| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 73.72 | 19.1% | 25.2% |
| Total Income | 74.84 | 18.3% | 25.6% |
| Expenditure | 99.24 | 20.4% | 28.6% |
| PBT | -24.41 | 26.1% | 36.7% |
| Net Profit | -24.42 | 26.1% | 36.7% |
| OPM | -9.07% | 2.99pp | 53.18pp |
| NPM | -32.63% | 3.43pp | 5.71pp |
| EPS | 11.35 | 32.6% | 157.7% |
Astec Lifesciences Reports Q2 FY26 Financial Results: EBITDA Loss Narrows to Rs. 5.6 Crore
29 Oct 2025 · 29 Oct 2025, 07:40 pm
Summary
Astec Lifesciences Ltd. has reported its financial results for the second quarter and half year ended September 30, 2025. The company's consolidated total income stood at Rs. 74.8 crore in Q2FY26, down from Rs. 100.5 crore in Q2FY25. The consolidated EBITDA loss narrowed to Rs. 5.6 crore in Q2FY26 from Rs. 17.7 crore in Q2 FY25.
Key Highlights
- 1
The Company reported consolidated total income of Rs. 74.8 crore in Q2FY26 as compared to Rs. 100.5 crore in Q2FY25.
- 2
The Company reported consolidated EBITDA loss of Rs. 5.6 crore in Q2FY26 as compared to EBITDA loss of Rs. 17.7 crore in Q2 FY25.
- 3
The Company reported consolidated total income of Rs. 166.4 crore in H1 FY26 as compared to Rs. 170.8 crore in H1 FY25.
- 4
The Company reported consolidated EBITDA loss of Rs. 16.1 crore in H1 FY26 as compared to loss of Rs. 63.1 crore in H1 FY25.
Management Comments
Mr. N B Godrej
Astec recorded year-on-year and sequential improvement in its performance in Q2 FY26. The EBITDA loss narrowed to 5.6 crore, reflecting a positive trend compared to previous quarters. This improvement was largely driven by higher volumes and better gross margins in the Enterprise business.
Informational and educational content only. Not investment advice.